HES5 and prostate cancer: Treatment of LNCaP cells with the DNA demethylating agent 5-aza-2′-deoxycytidine caused de-repression of the HES5 gene (Fig. 3b), consistent with active epigenetic silencing of the HES5 gene in prostate cancer cells.